1. Home
  2. OPRA vs AVLN Comparison

OPRA vs AVLN Comparison

Compare OPRA & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Opera Limited

OPRA

Opera Limited

HOLD

Current Price

$19.29

Market Cap

1.6B

Sector

Technology

ML Signal

HOLD

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$27.96

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OPRA
AVLN
Founded
1996
N/A
Country
Norway
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2018
2026

Fundamental Metrics

Financial Performance
Metric
OPRA
AVLN
Price
$19.29
$27.96
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$21.50
N/A
AVG Volume (30 Days)
335.1K
520.1K
Earning Date
04-28-2026
N/A
Dividend Yield
4.61%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$21.29
N/A
Revenue Next Year
$15.34
N/A
P/E Ratio
$13.62
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.71
$27.33
52 Week High
$21.06
$33.32

Technical Indicators

Market Signals
Indicator
OPRA
AVLN
Relative Strength Index (RSI) 53.61 32.04
Support Level $16.96 $27.37
Resistance Level $19.43 $29.48
Average True Range (ATR) 0.71 2.48
MACD -0.02 -0.30
Stochastic Oscillator 51.41 14.40

Price Performance

Historical Comparison
OPRA
AVLN

About OPRA Opera Limited

Opera Ltd is a consumer internet software company providing a diversified portfolio of high-performance web browsers and adjacent digital services to engaged user base The company has transitioned from browser developer to multi-faceted platform offering a products and services that include PC and mobile browsers, its Opera Gaming portals and development tools, Opera News content platforms, Opera Ads platform, as well as a number of AI and web3 products and services, such as MiniPay and Opera AI, to a user base.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: